Does a weight-loss injection protect the heart? What the SELECT trial found

Portfolio sample · Research summary for a general audience · Approximately 700 words
Audience: Health-interested readers of a health platform or newsletter.
Purpose: To explain a major clinical trial accurately, including absolute risk, side effects and limitations.
Evidence base: The SELECT trial primary results (New England Journal of Medicine, 2023), its published design paper and its prespecified weight-loss analysis (Nature Medicine, 2024).
Status: Self-initiated writing sample. Not commissioned or clinically reviewed.

Headlines said semaglutide cut heart attacks and strokes by 20%. Here is what that number means, and what it doesn't.

In 2023, a large clinical trial called SELECT reported that semaglutide, the medicine sold for weight management as Wegovy, lowered the risk of heart attacks, strokes and deaths from heart disease. The news was widely covered. This summary explains what the study did, what it found and how to read the results.

What question did the study ask?

Semaglutide was already known to help people lose weight and, in people with diabetes, to lower blood glucose and cardiovascular risk. SELECT asked a different question: in people who already have heart disease and are overweight, but do not have diabetes, does semaglutide reduce serious heart and circulation problems?1,2

How was it done?

SELECT was a randomised, double-blind, placebo-controlled trial, the strongest type of study for testing whether a treatment works. It included 17,604 adults aged 45 or over. Everyone had existing cardiovascular disease, such as a previous heart attack or stroke, and a body mass index (BMI) of 27 or higher. No one had diabetes.

Participants were randomly assigned to a weekly injection of semaglutide 2.4 mg or a placebo (a dummy injection), and were followed for an average of 39.8 months, just over three years. Neither the participants nor the researchers knew who was receiving which.1,2

What did it find?

The researchers counted how many people had a heart attack, a stroke or died from cardiovascular disease:

  • Semaglutide group: 569 of 8,803 people (6.5%)
  • Placebo group: 701 of 8,801 people (8.0%)

This corresponds to a hazard ratio of 0.80 (95% confidence interval 0.72 to 0.90). In plain terms, the risk of these events was about 20% lower in the semaglutide group, and the result is very unlikely to be due to chance. This is where the headline figure comes from.1

Relative risk versus absolute risk

A 20% reduction is a relative figure, and relative figures can sound larger than the difference a person would notice. The absolute difference was 1.5 percentage points: 8.0% minus 6.5%. As a rough guide, this means around 67 people would need to take semaglutide for just over three years to prevent one of these events.

For outcomes as serious as heart attack and stroke, that is a meaningful benefit. But the absolute figure gives a more realistic picture of what the treatment is likely to do for one person than the 20% alone.

What happened to weight?

People taking semaglutide lost weight steadily for over a year and largely kept it off. After four years, average weight had fallen by 10.2% with semaglutide, compared with 1.5% with placebo.3

What about side effects?

Side effects caused 16.6% of people taking semaglutide to stop treatment permanently, compared with 8.2% of those taking placebo. Stomach and bowel problems, such as nausea and diarrhoea, were the most common reason.1,4 This matters in real life, because a medicine only helps if people can keep taking it.

What the study cannot tell us

  • Who it applies to. Everyone in the trial already had heart disease. The results do not show whether semaglutide prevents heart problems in people who have never had them.
  • Women. Only about 28% of participants were women, so the evidence is less certain for them.4
  • Why it worked. The study was not designed to show whether the benefit came from weight loss itself or from other effects of the medicine.
  • The longer term. Cardiovascular outcomes were followed for just over three years, a relatively short time for a medicine that people may take for many years.
  • Funding. The trial was funded by the manufacturer, Novo Nordisk. This is common for large drug trials and does not make the results wrong, but independent studies will add confidence.1

The bottom line

SELECT is a large, well-designed trial. It provides good evidence that semaglutide reduces serious cardiovascular events in adults who have heart disease and are overweight, but do not have diabetes. The benefit is real but moderate in absolute terms, side effects are common, and the results should not be stretched to groups who were not studied.

Anyone wondering whether this medicine is right for them should discuss it with their doctor, who can weigh the benefits and risks for their situation.

References

  1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232. https://doi.org/10.1056/NEJMoa2307563
  2. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020;229:61–69. https://doi.org/10.1016/j.ahj.2020.07.008
  3. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049–2057. https://doi.org/10.1038/s41591-024-02996-7
  4. American College of Cardiology. SELECT: Semaglutide vs. placebo in overweight or obese patients with pre-existing CVD, but without diabetes. Latest in Cardiology, November 2023. acc.org